Product Description

Fludarabine, a fluorinated purine nucleoside analog and DNA synthesis inhibitor, exhibits antitumor activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes.

Screeningbio‘s SW620/Fludarabine resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Fludarabine (Fludara) is a purine analog antimetabolite that, after intracellular phosphorylation to its active triphosphate form (F-ara-ATP), inhibits DNA synthesis by competitively inhibiting DNA polymerase and ribonucleotide reductase, and incorporates into nascent DNA strands, causing chain termination and DNA fragmentation. This leads to disruption of DNA replication, accumulation of cells in S‑phase, induction of apoptosis in proliferating lymphocytes, and is widely used in the treatment of chronic lymphocytic leukemia (CLL) and indolent non‑Hodgkin lymphomas. However, resistance to fludarabine remains a major clinical challenge that limits its long‑term efficacy.

Mechanistically, fludarabine resistance arises through multiple cellular adaptations. Reduced intracellular drug accumulation due to decreased expression or function of the equilibrative nucleoside transporter hENT1 (SLC29A1) impairs drug uptake, while upregulation of efflux transporters such as MRP1 (ABCC1) and other ATP‑binding cassette (ABC) transporters increases drug extrusion. Additionally, alterations in deoxycytidine kinase (dCK) activity—the key enzyme for fludarabine phosphorylation—or increased expression of 5'‑nucleotidase (which dephosphorylates the active metabolite) reduce the formation of cytotoxic F-ara-ATP. Activation of survival signaling pathways, including PI3K/Akt and NF‑κB, and overexpression of anti‑apoptotic Bcl‑2 family proteins (e.g., Bcl‑2, Mcl‑1) promote cell survival. Moreover, enhanced DNA repair capacity (e.g., upregulation of ATM/ATR‑mediated checkpoint responses or nucleotide excision repair) and the presence of TP53 mutations (which are common in CLL) confer significant resistance by impairing apoptosis. The tumor microenvironment, particularly interactions with bone marrow stromal cells or nurselike cells, provides additional survival signals through adhesion‑mediated protection and soluble factors.

Understanding these mechanisms is essential for developing strategies to overcome resistance. Potential approaches include combining fludarabine with other agents such as rituximab, cyclophosphamide, or novel targeted therapies (e.g., Bcl‑2 inhibitors like venetoclax, BTK inhibitors, or PI3Kδ inhibitors), using dose‑intensified regimens, or developing second‑generation purine analogs with altered metabolic profiles. Moreover, pretreatment assessment of hENT1 expression, dCK activity, and TP53 mutational status may guide patient selection for more effective, personalized treatment regimens.